Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Luran S MED 797S SPF30 is one of the first ASA materials in the market specifically for medical device housings
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
PEEK brings a new quality to dental care for patients
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Subscribe To Our Newsletter & Stay Updated
